Banco de Sabadell’s Vertex Pharmaceuticals VRTX Stock Holding History

Banco de Sabadell’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-579	Closed	-$203K	–	85
2023 Q3	$203K	Hold	579	–	–	0.18%	67
2023 Q2	$203K	Hold	579	–	–	0.16%	63
2023 Q1	$182K	Hold	579	–	–	0.15%	62
2022 Q4	$23K	Hold	579	–	–	0.02%	79
2022 Q3	$169K	Hold	579	–	–	0.14%	67
2022 Q2	$162K	Hold	579	–	–	0.14%	61
2022 Q1	$150K	Sell	579 -171	-23%	-$40.6K	0.09%	70
2021 Q4	$166K	Hold	750	–	–	0.09%	73
2021 Q3	$136K	Hold	750	–	–	0.09%	78
2021 Q2	$150K	Sell	750 -1,325	-64%	-$277K	0.1%	91
2021 Q1	$446K	Buy	2,075 +1,100	+113%	+$242K	0.05%	174
2020 Q4	$228K	Sell	975 -9,810	-91%	-$2.25M	0.02%	225
2020 Q3	$2.91M	Buy	+10,785	New	+$2.98M	0.33%	74
2019 Q4	–	Sell	-975	Closed	-$164K	–	367
2019 Q3	$164K	Hold	975	–	–	0.02%	269
2019 Q2	$179K	Hold	975	–	–	0.02%	279
2019 Q1	$179K	Hold	975	–	–	0.02%	285
2018 Q4	$159K	Hold	975	–	–	0.02%	321
2018 Q3	$186K	Sell	975 -7,771	-89%	-$1.38M	0.02%	344
2018 Q2	$1.39M	Buy	+8,746	New	+$1.36M	0.18%	135

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Banco de Sabadell's VRTX Position: Q4 2023 in Review

Banco de Sabadell sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 579 shares — an estimated $203K sold.

Banco de Sabadell first reported a position in VRTX in Q2 2018 and held it in 19 quarters. The position peaked at $2.91M in Q3 2020. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Banco de Sabadell reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Banco de Sabadell sold 579 Vertex Pharmaceuticals shares in Q4 2023, an estimated $203K.
Banco de Sabadell first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 19 quarters.
Banco de Sabadell's Vertex Pharmaceuticals position peaked at $2.91M in Q3 2020.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Banco de Sabadell's 13F filing for Q4 2023, filed 9 Feb 2024.